Clinical trial Recruiting at 1 site Observational Ages 18 and up Women only

Monitoring the effects of bempedoic acid during pregnancy

Official title: A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Women Exposed to Bempedoic Acid or Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) During Pregnancy

Run by Esperion Therapeutics, Inc. · NCT05103254 · Data updated 2026-11-12

This study looks at how bempedoic acid affects pregnant women and their babies during pregnancy and the first year of life.

More Pregnancy trials

Quick facts

Study typeObservational
Ages18 Years and up
SexWomen only
Enrollment20 (estimated)
SponsorEsperion Therapeutics, Inc.
Industry-sponsored
Locations1 site (Morrisville, North Carolina)
StatusRecruiting
StartedSeptember 1, 2021
Main results expectedMay 2032
Study endsMay 2032
Registry record updatedMay 17, 2024
Trial IDNCT05103254 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are pregnant women who have taken at least one dose of bempedoic acid or the bempedoic acid/ezetimibe combination during their pregnancy.

Probably not a fit

Patients who have not been exposed to bempedoic acid or the combination therapy during pregnancy will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on pregnant females who have been exposed to bempedoic acid or a fixed combination of bempedoic acid and ezetimibe. It aims to collect data on the outcomes of these pregnancies and the health of infants during their first year of life. The study will gather information on both maternal and infant health to better understand the implications of bempedoic acid exposure during pregnancy. Participants will be monitored throughout their pregnancy and for a year after giving birth.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the safety and effects of bempedoic acid during pregnancy, guiding future treatment options for pregnant women with hyperlipidemia.

How similar studies have gone: While there may be limited data on the specific effects of bempedoic acid during pregnancy, similar observational studies on drug exposure in pregnancy have provided important safety information in the past.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Exposure to at least 1 dose of bempedoic acid or bempedoic acid/ezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \[LMP\] to pregnancy outcome

Exclusion Criteria:

Where it's running

  • Evidera, PPD business unit
    Morrisville, North Carolina, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.